Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug OLN324 tested for wet AMD and diabetic swelling

NCT ID NCT07484074

Disease control Sponsor: Ollin Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an investigational eye injection called OLN324 in 164 adults with either wet age-related macular degeneration (AMD) or diabetic macular edema (DME). The main goal was to check safety and how the drug moves in the body, with a preliminary look at whether it might improve vision. Participants received either OLN324 or an existing treatment (faricimab) to compare results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OLN324 (eye injection)
What this could lead to
If successful, this could lead to a new treatment option for wet AMD and diabetic macular edema, potentially reducing the need for frequent eye injections.
What could go wrong
This is an early Phase 1b trial focused on safety, so it is too soon to know if OLN324 works. The drug may not prove effective or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

164 people

The number who actually took part.

Started

Feb 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity * DME patients must be ≥ 18 years of age, nAMD patients must be ≥ 50 years of age * Diagnosis of either DME or nAMD. nAMD patients must be treatment naïve. DME patients can be either treatment naïve or treatment experienced * DME patients must have best corrected visual acuity of 78 to 25 letters * nAMD patients must have best corrected visual acuity of 80 to 25 letters Exclusion Criteria: * If pregnant or breastfeeding * History of cataract surgery and/or Yttrium-Aluminum Garnet (YAG) for removal of posterior capsular opacification (PCO) within 90 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic macular edema (DME) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic macular edema macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic macular edema (DME) Neovascular (WET) age-related macular degeneration

Contacts and locations

Locations

  • Abilene, TX

    Abilene, Texas, 79606, United States

  • Arecibo, Puerto Rico

    Arecibo, 00612-4368, Puerto Rico

  • Arlington, TX

    Arlington, Texas, 76012, United States

  • Austin, TX

    Austin, Texas, 78705, United States

  • Bellaire, TX

    Bellaire, Texas, 77401, United States

  • Dallas, TX

    Dallas, Texas, 75231, United States

  • Fort Myers, FL

    Fort Myers, Florida, 33912, United States

  • Germantown, TN

    Germantown, Tennessee, 38138, United States

  • Glendale, CA

    Glendale, California, 91204, United States

  • Grand Rapids, MI

    Grand Rapids, Michigan, 49546, United States

  • Hagerstown, MD

    Hagerstown, Maryland, 21740, United States

  • Katy, TX

    Katy, Texas, 77494, United States

  • Oak Forest, IL

    Oak Forest, Illinois, 60452, United States

  • Pasadena, CA

    Pasadena, California, 91107, United States

  • Phoenix, AZ

    Phoenix, Arizona, 85016, United States

  • Plano, TX

    Plano, Texas, 75075, United States

  • Reno, NV

    Reno, Nevada, 89502, United States

  • Round Rock, TX

    Round Rock, Texas, 78681, United States

  • Sacramento, CA

    Sacramento, California, 95825, United States

  • Saint Petersburg, FL

    St. Petersburg, Florida, 33711, United States

  • San Antonio, TX

    San Antonio, Texas, 78240, United States

  • San Marcos, TX

    San Marcos, Texas, 78666, United States

  • Schertz, TX

    Schertz, Texas, 78154, United States

  • Springfield, OR

    Springfield, Oregon, 97477, United States

  • The Woodlands, TX

    The Woodlands, Texas, 77384, United States

  • Tulsa, OK

    Tulsa, Oklahoma, 74114, United States

  • Wake Forest, NC

    Wake Forest, North Carolina, 27587, United States

  • Walnut Creek, CA

    Walnut Creek, California, 94598, United States

  • Waterford, CT

    Waterford, Connecticut, 06385, United States

  • Winter Haven, FL

    Winter Haven, Florida, 33880, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.